Hans Schreiber Selected Research

Hans Schreiber Research Topics

Disease

59	Neoplasms (Cancer) 01/2024 - 10/2002
4	Neoplasm Metastasis (Metastasis) 01/2020 - 08/2007
3	Breast Neoplasms (Breast Cancer) 01/2024 - 01/2020
2	Carcinogenesis 11/2020 - 12/2004
2	Carcinoma (Carcinomatosis) 01/2020 - 08/2007
1	Ovarian Neoplasms (Ovarian Cancer) 01/2023
1	Hematologic Neoplasms (Hematological Malignancy) 01/2023
1	Body Weight (Weight, Body) 01/2020
1	Triple Negative Breast Neoplasms 01/2020
1	Squamous Cell Carcinoma of Head and Neck 01/2020
1	Adenocarcinoma 01/2016
1	Melanoma (Melanoma, Malignant) 08/2013
1	Bites and Stings (Sting) 09/2012
1	Leukemia 02/2012
1	Autoimmune Diseases (Autoimmune Disease) 08/2010
1	Brain Neoplasms (Brain Tumor) 08/2009
1	Fibrosarcoma 12/2006
1	Inflammation (Inflammations) 12/2004
1	Venezuelan Equine Encephalomyelitis 10/2002

Drug/Important Bio-Agent (IBA)

33	AntigensIBA 01/2022 - 12/2002
12	Neoplasm Antigens (Tumor Antigens)IBA 06/2016 - 12/2002
9	T-Cell Antigen Receptors (T-Cell Receptor)IBA 04/2024 - 01/2007
9	CytokinesIBA 01/2024 - 03/2004
9	Peptides (Polypeptides)IBA 01/2020 - 06/2005
7	Chimeric Antigen ReceptorsIBA 01/2023 - 09/2012
7	Proteins (Proteins, Gene)FDA Link 01/2020 - 04/2003
6	EpitopesIBA 01/2020 - 10/2002
6	Monoclonal AntibodiesIBA 01/2019 - 10/2006
5	GlycopeptidesIBA 01/2020 - 06/2010
4	AntibodiesIBA 01/2024 - 01/2003
4	Glycoproteins (Glycoprotein)IBA 01/2020 - 08/2007
3	LyP-1 peptideIBA 01/2024 - 01/2020
3	Immune Checkpoint InhibitorsIBA 01/2020 - 01/2017
3	Polysaccharides (Glycans)IBA 01/2020 - 10/2006
3	AutoantigensIBA 01/2016 - 12/2003
2	CarcinogensIBA 11/2020 - 12/2004
2	Tn antigenIBA 01/2020 - 06/2010
2	Surface Antigens (Surface Antigen)IBA 01/2020 - 01/2016
2	CarbohydratesIBA 01/2020 - 06/2010
2	Serine (L-Serine)FDA Link 01/2020 - 06/2010
2	Threonine (L-Threonine)FDA Link 01/2020 - 06/2010
2	AcetylgalactosamineIBA 01/2020 - 06/2010
2	superagonist SIYRIBA 01/2017 - 08/2009
2	RNA (Ribonucleic Acid)IBA 01/2016 - 10/2002
2	LigandsIBA 12/2013 - 02/2012
2	Interleukin-15 (Interleukin 15)IBA 05/2013 - 04/2012
2	Histocompatibility Antigens Class IIBA 05/2012 - 06/2011
2	PerforinIBA 04/2012 - 04/2008
2	Interferon-gamma (Interferon, gamma)IBA 06/2011 - 03/2005
2	VaccinesIBA 06/2010 - 10/2002
2	Immunoglobulin G (IgG)IBA 04/2003 - 01/2003
1	Indicators and Reagents (Reagents)IBA 12/2021
1	Estrogens (Estrogen)FDA Link 11/2020
1	CalciumIBA 01/2020
1	Death Domain ReceptorsIBA 01/2020
1	SugarsIBA 01/2020
1	Tartrate-Resistant Acid PhosphataseIBA 01/2020
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2020
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2020
1	Isoantigens (Alloantigen)IBA 01/2017
1	Tumor Viral Antigens (Large T Antigen)IBA 01/2016
1	CollagenIBA 01/2016
1	NucleotidesIBA 01/2016
1	Mucin-1 (CA 15-3 Antigen)IBA 01/2016
1	Collagen Type I (Type I Collagen)IBA 01/2016
1	Cancer VaccinesIBA 01/2014
1	Bacterial VaccinesIBA 08/2013
1	Blocking AntibodiesIBA 08/2013
1	polyvinylsiloxane caoutchoucIBA 11/2012
1	SialomucinsIBA 09/2012
1	Single-Chain AntibodiesIBA 09/2012
1	T-Cell Antigen Receptor-CD3 ComplexIBA 09/2012
1	DEAD-box RNA HelicasesIBA 05/2012
1	Interleukin-15 Receptors (Interleukin 15 Receptor)IBA 04/2012
1	I-antigenIBA 06/2011
1	Ribosomal Proteins (Ribosomal Protein)IBA 08/2010
1	RibonucleoproteinsIBA 08/2010
1	OligosaccharidesIBA 06/2010
1	MonosaccharidesIBA 10/2006
1	GlycosyltransferasesIBA 10/2006
1	Mutant Proteins (Protein, Mutant)IBA 10/2006
1	Interleukin-6 (Interleukin 6)IBA 12/2004
1	InterferonsIBA 12/2004
1	Fas Ligand Protein (Fas Ligand)IBA 12/2004
1	Interleukin-18 (Interleukin 18)IBA 03/2004
1	Interleukin-12 (IL 12)IBA 03/2004
1	ChemokinesIBA 02/2004
1	Tamoxifen FDA LinkGeneric 04/2003
1	HLA-A*02:01 antigenIBA 10/2002
1	DNA (Deoxyribonucleic Acid)IBA 10/2002

Therapy/Procedure

19	Therapeutics 01/2024 - 10/2006
14	Immunotherapy 01/2022 - 12/2003
1	Lymph Node Excision (Lymph Node Dissection) 01/2020
1	Injections 09/2012
1	Cell- and Tissue-Based Therapy (Cell Therapy) 05/2012
1	Drug Therapy (Chemotherapy) 08/2007
1	Aftercare (After-Treatment) 01/2007
1	Ligation 12/2006